Phase 2/3 Outsourced Spend Across Provider Types
By Rebecca McAvoy, VP of Market Research, Industry Standard Research
Industry Standard Research conducted a 2022 survey with outsourcers of Phase 2/3 clinical development activities to better understand the dynamics in this space. Learning how respondents from sponsor organizations apportion their outsourced work across different provider types was of particular interest.
Overall, half of Phase 2/3 outsourcing spend goes to large, full-service CROs (51%) while one-quarter of spend (26%) goes to midsize, multi-service CROs. Small or niche service CROs and academic medical centers (AMCs) receive the remaining 14% and 9% of spend, respectively.
Get unlimited access to:
Enter your credentials below to log in. Not yet a member of Life Science Leader? Subscribe today.